Study title: To estimate the survival of bone marrow transplant (BMT) subjects randomized to receive cytomegalovirus (CMV) prophylaxis with intravenous (IV) acyclovir (ACV) followed by either oral valaciclovir (VACV) or IV ganciclovir (GCV).
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Virus Diseases | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: VALACICLOVIR | |||||
ATC code: | |||||
Document link: Study 123-039 (HS2A3005) Valaciclovir.xls | |||||
Document date: 2011-09-23 | |||||
Study number: 123-039 (HS2A3005) | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |